REASURE
Phase II open label study of biomarkers to assess response in patients with metastatic castration-resistant prostate cancer treated with radium-223.
Disease site: Urological cancers Prostate cancer
Status: Closed
Trial details
REASURE is a phase II, multicentre, randomised trial of radium-223 incorporating diffusion-weighted MRI (DW-MRI) and PET imaging with collection of blood, urine and bone marrow samples. REASURE aims to identify potential markers of response to treatment with radium-223 in patients with castration-resistant prostate cancer with bone metastases.
38 patients will be recruited from four UK sites over 18 months. Patients will be randomised to receive a monthly radium-223 injection at a dose of either 50 kBq/kg or 80 kBq/kg for up to 6 months. Patients will be followed up every 4 months for 1 year after their last treatment of radium-223.
Further information for healthcare professionals
Further information for potential participants
Further information
Chief Investigator: Professor Chris Parker, The Royal Marsden NHS Foundation Trust
ICR-CTSU Scientific Lead: Professor Emma Hall
Trial management contact: [email protected]
ISRCTN: 17805587
Sponsor: The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Funding: Bayer HealthCare Pharmaceuticals Inc.
View REASURE on the National Institute for Health Research website: NIHR - Be Part Of Research
A plain English summary of the TNT trial is available from Cancer Research UK.
Publications and presentations
There have been no presentations or publications to date.
Remembering former ICR Chief Executive Professor Peter Garland
